Lytix Biopharma presents first half and second quarter 2023 results
Building a Phase II evidence base Oslo, 31 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today releases its first half and second quarter 2023 results.Chief Executive Officer of Lytix Biopharma, Dr. Øystein Rekdal, commented: “We have continued to make positive progress as we build a clinical Phase II evidence base for our lead compound LTX-315. Earlier this month we received strong data from Part 1 of Verrica Pharmaceuticals’ ongoing clinical Phase II study and more recently we announced the